FDA mandates warning labels for GLP-1 drugs over rare eye risk

The Washington Post • 10 Նոյ 21:48

The FDA announced that manufacturers of GLP-1 medications must add a label warning about a possible increase in the risk of non-arteritic anterior ischemic optic neuropathy, a rare condition often called “eye stroke.”

Global News • 10 Նոյ 18:17

The FDA will require all GLP-1 medications to carry a warning about the rare risk of non-arteritic anterior ischemic optic neuropathy, a condition that can cause permanent vision loss.

Ars Technica • 10 Նոյ 14:43

The U.S. Food and Drug Administration will mandate that manufacturers of GLP-1 receptor agonists add a warning about non-arteritic anterior ischemic optic neuropathy to product labels, citing a small but possible increased risk.

The Independent • 10 Նոյ 14:35

The U.S. Food and Drug Administration will mandate warning labels for GLP-1 medications after a review linked them to a rare optic-nerve condition, NAION, affecting vision.

Fox Business • 10 Նոյ 13:10

The FDA has ordered new warning labels for GLP-1 medications after a review found a higher incidence of a rare optic-nerve disorder among users.

STAT • 10 Նոյ 06:26

The FDA warned that drugs in the GLP-1 class could be linked to non-arteritic anterior ischemic optic neuropathy, a rare condition that can cause sudden vision loss.

NBC News • 9 Նոյ 18:14

The FDA ordered manufacturers of GLP-1 medications to add warnings about a possible increased risk of nonarteritic anterior ischemic optic neuropathy, a rare condition that can cause sudden, permanent vision loss.